<DOC>
	<DOCNO>NCT02849613</DOCNO>
	<brief_summary>Stroke second lead cause death world population . When fatal , stroke often result disability , secondary health problem affect patient also family . Building emerge preclinical pilot clinical evidence , RESSTORE focus clinical assessment regenerative cell therapy improve stroke recovery patient quality life .</brief_summary>
	<brief_title>Regenerative Stem Cell Therapy Stroke Europe</brief_title>
	<detailed_description>RESSTORE European multicentre randomise phase IIb explore efficacy ( functional recovery ) safety intravenous infusion allogenic adipose tissue derive mesenchymal stem cell ( ADSC ) 400 stroke patient . Therapeutic effect ADSCs assess monitored patient use clinical rating scale , multimodal MRI blood biomarkers . The European regenerative therapy capacity ( France , Spain , Finland , United Kingdom Czech Republic ) , develop RESSTORE cover full value chain field ( large scale GMP cell production , clinical testing , biomarkers discovery , understand restore mechanism , biobanking ... ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Hemispheric ischemic stroke ( &gt; 1.5cm ) Inclusion 1 4 day poststroke NIHSS &gt; = 7 No craniectomy Able follow rehabilitation program Modified Rankin scale = 0 stroke onset Coma Severe leucoariosis Previous stroke Active endocarditis , pneumonia , AIDS , active hepatic disease due HBV HCV History cancer Pregnancy , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cell therapy</keyword>
	<keyword>stem cell</keyword>
	<keyword>transplantation</keyword>
	<keyword>graft</keyword>
	<keyword>recovery</keyword>
	<keyword>repair</keyword>
	<keyword>stroke</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>regenerative</keyword>
</DOC>